| Code | CSB-RA008545MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Imeroprubart, targeting the neonatal Fc receptor (FCGRT, FcRn). FCGRT plays a critical role in IgG homeostasis by binding to the Fc region of immunoglobulin G at acidic pH, protecting IgG antibodies from lysosomal degradation and recycling them back into circulation. This receptor is also responsible for the transplacental transfer of maternal IgG to the fetus and maintaining serum albumin levels. Dysregulation of FCGRT-mediated IgG recycling is implicated in various autoimmune conditions where pathogenic autoantibodies contribute to disease pathology, including myasthenia gravis, immune thrombocytopenia, and pemphigus.
Imeroprubart is a therapeutic monoclonal antibody that blocks the interaction between FCGRT and IgG, thereby reducing pathogenic IgG levels in autoimmune diseases. This biosimilar antibody provides researchers with a valuable tool for investigating FCGRT biology, studying IgG metabolism and homeostasis, exploring mechanisms of maternal-fetal antibody transfer, and evaluating therapeutic strategies for antibody-mediated autoimmune disorders.
There are currently no reviews for this product.